Universal Health Services, Inc. (UHS) Cash Flow Statement

The OCF/NI ratio has been erratic, with peaks in 2024Q2 and 2024Q4 (2.35 and 1.98) and troughs in 2025Q3 (1.02) and 2026Q1 (1.15). This volatility suggests that net income is not consistently backed by cash generation, likely due to swings in working capital. The recent ratio of 1.24 in 2026Q2, while above 1, indicates a modest cushion, but the inconsistency warrants monitoring for potential accrual-based earnings management.

FCF has been volatile, with a low of $85.0M in 2024Q3 and a high of $437.9M in 2024Q2. The recent quarter's $215.7M FCF is a recovery from the $133.1M in 2025Q3, but the margin is still compressed relative to earlier periods. This suggests that while operational cash flow is stabilizing, capital expenditures are absorbing a significant portion, limiting free cash flow growth. The trajectory implies that UHS is in a capital-intensive phase, potentially investing in capacity expansion.

CapEx/Revenue has hovered between 4.8% and 6.3%, with the latest quarter at 4.9%. This consistency suggests that UHS is maintaining a stable capital expenditure program, likely for both maintenance and growth. The absolute CapEx has increased from $208.5M in 2024Q1 to $227.6M in 2026Q2, aligning with revenue growth. This indicates a deliberate strategy to expand capacity, particularly in behavioral health, which may support future revenue but also pressures near-term FCF.

The working capital line has been a major source of volatility, with positive contributions in 2024Q2 and 2025Q2 (e.g., +$210.9M and +$71.5M) and negative in most other quarters. This pattern suggests that UHS's cash conversion cycle is sensitive to timing of receivables and payables, possibly due to payer mix and government reimbursement delays. The negative working capital changes in recent quarters (e.g., -$111.0M in 2026Q2) may indicate tighter collections or increased inventory, which could pressure cash flow if sustained.

Buybacks have been substantial and increasing, from $95.9M in 2024Q2 to $320.8M in 2026Q2, while dividends have remained flat around $12-13M per quarter. This aggressive repurchase activity suggests management views the stock as undervalued and is confident in cash generation. However, the buybacks are consuming a significant portion of FCF, which may limit flexibility for acquisitions or debt reduction. The consistent buyback program, despite volatile FCF, indicates a disciplined capital return policy.

The cumulative OCF/NI ratio is approximately 1.43, suggesting that UHS has generated significantly more cash than accounting earnings over this period. This divergence is likely due to non-cash charges like D&A (totaling ~$1.53B) and favorable working capital timing. However, the quarterly volatility in OCF/NI (ranging from 1.02 to 2.35) implies that the timing of cash collections is lumpy, and investors should not extrapolate the cumulative ratio to future quarters. The overall trend suggests that earnings are backed by cash, but the variability warrants caution.